Radiomics Features on Enhanced Computed Tomography Predict FOXP3 Expression and Clinical Prognosis in Patients with Head and Neck Squamous Cell Carcinoma

Overview

Journal J Imaging Inform Med

Publisher Springer Nature

Specialty Radiology

Date 2024 Feb 20

PMID 38376584

Authors

Yi Wang

Juan Ye

Kai Zhou

Nian Chen

Gang Huang

Guangyong Feng

Guihai Zhang

Xiaoxia Gou

Affiliations

Soon will be listed here.

Abstract

Forkhead box P3 (FOXP3) has been identified as a novel molecular marker in various types of cancer. The present study assessed the expression of FOXP3 in patients with head and neck squamous cell carcinoma (HNSCC) and its potential as a clinical prognostic indicator, and developed a radiomics model based on enhanced computed tomography (CT) imaging. Data from 483 patients with HNSCC were downloaded from the Cancer Genome Atlas for FOXP3 prognostic analysis and enhanced CT images from 139 patients included in the Cancer Imaging Archives, which were subjected to the maximum relevance and minimum redundancy and recursive feature elimination algorithms for radiomics feature extraction and processing. Logistic regression was used to build a model for predicting FOXP3 expression. A prognostic scoring system for radiomics score (RS), FOXP3, and patient clinicopathological factors was established to predict patient survival. The area under the receiver operating characteristic (ROC) curve (AUC) and calibration curve and decision curve analysis (DCA) were used to evaluate model performance. Furthermore, the relationship between FOXP3 and the immune microenvironment, as well as the association between RS and immune checkpoint-related genes, was analyzed. Results of analysis revealed that patients with HNSCC and high FOXP3 mRNA expression exhibited better overall survival. Immune infiltration analysis revealed that FOXP3 had a positive correlation with CD4 and CD8 T cells and other immune cells. The 8 best radiomics features were selected to construct the radiomics model. In the FOXP3 expression prediction model, the AUC values were 0.707 and 0.702 for the training and validation sets, respectively. Additionally, the calibration curve and DCA demonstrated the positive diagnostic utility of the model. RS was correlated with immune checkpoint-related genes such as ICOS, CTLA4, and PDCD1. A predictive nomogram was established, the AUCs were 0.87, 0.787, and 0.801 at 12, 24, and 36 months, respectively, and DCA demonstrated the high clinical applicability of the nomogram. The enhanced CT radiomics model can predict expression of FOXP3 and prognosis in patients with HNSCC. As such, FOXP3 may be used as a novel prognostic marker to improve individualized clinical diagnosis and treatment decisions.

References

Lechner M, Liu J, Masterson L, Fenton T . HPV-associated oropharyngeal cancer: epidemiology, molecular biology and clinical management. Nat Rev Clin Oncol. 2022; 19(5):306-327. PMC: 8805140. DOI: 10.1038/s41571-022-00603-7. View

Deneka A, Baca Y, Serebriiskii I, Nicolas E, Parker M, Nguyen T . Association of TP53 and CDKN2A Mutation Profile with Tumor Mutation Burden in Head and Neck Cancer. Clin Cancer Res. 2022; 28(9):1925-1937. PMC: 9186806. DOI: 10.1158/1078-0432.CCR-21-4316. View

Schinke H, Shi E, Lin Z, Quadt T, Kranz G, Zhou J . A transcriptomic map of EGFR-induced epithelial-to-mesenchymal transition identifies prognostic and therapeutic targets for head and neck cancer. Mol Cancer. 2022; 21(1):178. PMC: 9454230. DOI: 10.1186/s12943-022-01646-1. View

Chen J, Sun H, Yang Y, Chen H, Yu X, Wu W . Reprogramming immunosuppressive myeloid cells by activated T cells promotes the response to anti-PD-1 therapy in colorectal cancer. Signal Transduct Target Ther. 2021; 6(1):4. PMC: 7791142. DOI: 10.1038/s41392-020-00377-3. View

Sakaguchi S, Yamaguchi T, Nomura T, Ono M . Regulatory T cells and immune tolerance. Cell. 2008; 133(5):775-87. DOI: 10.1016/j.cell.2008.05.009. View

Cui X, Zhang C, Xu Z, Wang S, Li X, Stringer-Reasor E . Dual CRISPR interference and activation for targeted reactivation of X-linked endogenous FOXP3 in human breast cancer cells. Mol Cancer. 2022; 21(1):38. PMC: 8819949. DOI: 10.1186/s12943-021-01472-x. View

Peng J, Yang S, Ng C, Chen G . The role of FOXP3 in non-small cell lung cancer and its therapeutic potentials. Pharmacol Ther. 2022; 241:108333. DOI: 10.1016/j.pharmthera.2022.108333. View

Ma S, Deng W, Liu J, Mao L, Yu G, Bu L . Blockade of adenosine A2A receptor enhances CD8 T cells response and decreases regulatory T cells in head and neck squamous cell carcinoma. Mol Cancer. 2017; 16(1):99. PMC: 5461710. DOI: 10.1186/s12943-017-0665-0. View

Oreiller V, Andrearczyk V, Jreige M, Boughdad S, Elhalawani H, Castelli J . Head and neck tumor segmentation in PET/CT: The HECKTOR challenge. Med Image Anal. 2022; 77:102336. DOI: 10.1016/j.media.2021.102336. View

10.

Chen Q, Zhang L, Liu S, You J, Chen L, Jin Z . Radiomics in precision medicine for gastric cancer: opportunities and challenges. Eur Radiol. 2022; 32(9):5852-5868. DOI: 10.1007/s00330-022-08704-8. View

11.

Zhang Q, Wang K, Zhou Z, Qin G, Wang L, Li P . Predicting local persistence/recurrence after radiation therapy for head and neck cancer from PET/CT using a multi-objective, multi-classifier radiomics model. Front Oncol. 2022; 12:955712. PMC: 9557184. DOI: 10.3389/fonc.2022.955712. View

12.

Fang Q, Chen H . The significance of m6A RNA methylation regulators in predicting the prognosis and clinical course of HBV-related hepatocellular carcinoma. Mol Med. 2020; 26(1):60. PMC: 7302147. DOI: 10.1186/s10020-020-00185-z. View

13.

Peng H, Long F, Ding C . Feature selection based on mutual information: criteria of max-dependency, max-relevance, and min-redundancy. IEEE Trans Pattern Anal Mach Intell. 2005; 27(8):1226-38. DOI: 10.1109/TPAMI.2005.159. View

14.

Okuyama K, Yanamoto S . TMEM16A as a potential treatment target for head and neck cancer. J Exp Clin Cancer Res. 2022; 41(1):196. PMC: 9172006. DOI: 10.1186/s13046-022-02405-2. View

15.

Shonka Jr D, Ho A, Chintakuntlawar A, Geiger J, Park J, Seetharamu N . American Head and Neck Society Endocrine Surgery Section and International Thyroid Oncology Group consensus statement on mutational testing in thyroid cancer: Defining advanced thyroid cancer and its targeted treatment. Head Neck. 2022; 44(6):1277-1300. PMC: 9332138. DOI: 10.1002/hed.27025. View

16.

Qiu Y, Ke S, Chen J, Qin Z, Zhang W, Yuan Y . FOXP3+ regulatory T cells and the immune escape in solid tumours. Front Immunol. 2022; 13:982986. PMC: 9774953. DOI: 10.3389/fimmu.2022.982986. View

17.

Wang J, Gong R, Zhao C, Lei K, Sun X, Ren H . Human FOXP3 and tumour microenvironment. Immunology. 2022; 168(2):248-255. DOI: 10.1111/imm.13520. View

18.

Ma L, Diao B, Huang Z, Wang B, Yu J, Meng X . The efficacy and possible mechanisms of immune checkpoint inhibitors in treating non-small cell lung cancer patients with epidermal growth factor receptor mutation. Cancer Commun (Lond). 2021; 41(12):1314-1330. PMC: 8696228. DOI: 10.1002/cac2.12229. View

19.

Chen B, Zhao J, Zhang D, Zheng A, Wu G . Immunotherapy of Cancer by Targeting Regulatory T cells. Int Immunopharmacol. 2022; 104:108469. DOI: 10.1016/j.intimp.2021.108469. View

20.

Chen H, Luan X, Paholak H, Burnett J, Stevers N, Sansanaphongpricha K . Depleting tumor-associated Tregs via nanoparticle-mediated hyperthermia to enhance anti-CTLA-4 immunotherapy. Nanomedicine (Lond). 2019; 15(1):77-92. PMC: 7132783. DOI: 10.2217/nnm-2019-0190. View